Item 8.01. Other Events.

On January 22, 2013, Telik, Inc. ("Telik") announced the completion of an End of Phase 2 meeting with the U.S. Food and Drug Administration ("FDA") and preliminary agreement regarding the design of a Phase 3 trial of Telintra® for the treatment of Low to Intermediate-1 risk myelodysplastic syndrome. The press release announcing the completion of an End of Phase 2 meeting and preliminary agreement is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)

99.1 Press Release, dated January 22, 2013, entitled "Telik Announces Preliminary Agreement on Design of Phase 3 Registration Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome."

---